Meritage Portfolio Management Crispr Therapeutics Ag Transaction History

Meritage Portfolio Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 28, 2022	SELL	$70.09 - $111.29 $211,671 - $336,095	-3,020 Closed	0 $0
Q3 2021 Oct 26, 2021	BUY	$110.2 - $156.64 $38,900 - $55,293	353 Added 13.24%	3,020 $338,000
Q2 2021 Jul 26, 2021	BUY	$100.84 - $161.89 $31,058 - $49,862	308 Added 13.06%	2,667 $432,000
Q1 2021 Apr 27, 2021	BUY	$110.72 - $210.04 $91,122 - $172,862	823 Added 53.58%	2,359 $287,000
Q4 2020 Feb 03, 2021	BUY	$79.67 - $173.23 $122,373 - $266,081	1,536 New	1,536 $235,000

483

64.1M

1.64M

1.93M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.07B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Meritage Portfolio Management, based on Form 13F filings with the SEC.

Stay updated on Meritage Portfolio Management with notifications on news.